Theriva Biologics to Present Positive VCN-01 Data in Pancreatic Cancer Trial at AACR 2026
Event summary
- Theriva Biologics will present additional data from the VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic cancer at AACR 2026 on April 20, 2026.
- Tumor response, biomarker, and subgroup analyses support VCN-01's immune-mediated mode of action and improved outcomes across multiple subgroups.
- The company has aligned with FDA and EMA on a proposed Phase 3 trial for VCN-01 plus gemcitabine/nab-paclitaxel in first-line metastatic PDAC.
- Theriva plans a small study to assess whether more frequent and extended VCN-01 dosing could further improve outcomes.
The big picture
Theriva Biologics' upcoming presentation at AACR 2026 underscores the growing interest in oncolytic viruses as a therapeutic strategy for pancreatic cancer, a disease with high unmet medical need. The company's alignment with both the FDA and EMA on a Phase 3 trial design suggests a streamlined path to potential approval, which could position VCN-01 as a key player in the metastatic pancreatic cancer treatment landscape. The focus on biomarker and subgroup analyses also highlights the industry's shift towards personalized medicine and targeted therapies.
What we're watching
- Regulatory Alignment
- Whether the FDA and EMA alignment on the Phase 3 trial design will accelerate approval timelines for VCN-01.
- Clinical Efficacy
- How the additional data from the VIRAGE trial will impact investor confidence in VCN-01's potential as a treatment for metastatic pancreatic cancer.
- Dosing Optimization
- The pace at which Theriva can demonstrate the benefits of more frequent and extended VCN-01 dosing in future studies.
Related topics